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Cytokine signatures in chronic fatigue 
syndrome patients: a Case Control Study 
and the effect of anakinra treatment
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Abstract 
Background: Cytokine disturbances have been suggested to be associated with the Chronic Fatigue Syndrome/
Myalgic encephalomyelitis (CFS/ME) for decades.
Methods: Fifty female CFS patients were included in a study on the effect of the interleukin-1-receptor antagonist 
anakinra or placebo during 4 weeks. EDTA plasma was collected from patients before and directly after treatment. 
At baseline, plasma samples were collected at the same time from 48 healthy, age-matched female neighborhood 
controls. A panel of 92 inflammatory markers was determined in parallel in 1 μL samples using a ‘proximity extension 
assay’ (PEA) based immunoassay. Since Transforming growth factor beta (TGF-β) and interleukin-1 receptor antagonist 
(IL-1Ra) were not included in this platform, these cytokines were measured with ELISA.
Results: In CFS/ME patients, the ‘normalized protein expression’ value of IL-12p40 and CSF-1 was significantly higher 
(p value 0.0042 and 0.049, respectively). Furthermore, using LASSO regression, a combination of 47 markers yielded a 
prediction model with a corrected AUC of 0.73. After correction for multiple testing, anakinra had no effect on circu-
lating cytokines. TGF-β did not differ between patients and controls.
Conclusions: In conclusion, this study demonstrated increased IL-12p40 and CSF-1 concentrations in CFS/ME 
patients in addition to a set of predictive biomarkers. There was no effect of anakinra on circulating cytokines other 
than IL-1Ra.
Trial Registration: ClinicalTrials.gov Identifier: NCT02108210, Registered April 2014
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Background
Chronic fatigue syndrome/Myalgic encephalomyeli-
tis (CFS/ME) is a condition of unknown origin that is 
characterized by severe fatigue for more than 6 months 
leading to significant disability. To fulfill the CFS/ME 
criteria as recommended by the Centers for Disease 
control (CDC), patients also have to report at least four 
out of eight of the accompanying symptoms (e.g. muscle 
pain, post-exertional fatigue, headache, etc.) [1, 2]. With 
CFS/ME being an exclusionary diagnosis, patients often 
report to have symptoms for several years before being 
diagnosed [3]. Most of the current case definitions sug-
gest a collection of mandatory diagnostics to exclude 
common causes for fatigue such as anemia and thyroid 
illnesses [1, 4], but there is a need for more specific tests 
to diagnose patients. Another advantage of such a test 
is that it might be easier to define CFS/ME subgroups 
[5], for example those patients that would or would not 
respond to an immune intervention. Last but not least, a 
distinctive marker or set of markers may point to relevant 
pathogenetic mechanisms that can be further explored.
In the past years, numerous studies have been per-
formed searching for potential biomarkers [6]. Because 
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of the resemblance of CFS/ME with symptoms that char-
acterize immune activation, there has been a particular 
interest in the immune system with studies measuring 
lymphocyte subsets [7, 8], cytokine production [9–11], 
and single nucleotide polymorphisms in immune related 
genes [12, 13]. However, despite a large number of studies 
conducted, this has not led to a unified conclusion use-
ful for clinical practice. Studies are largely contradicting, 
and a recent systematic review on circulating cytokines 
did not find evidence for altered cytokine concentrations 
in CFS/ME, with the exception of transforming growth 
factor-beta (TGF-β) [14]. TGF-β appeared to be elevated 
in 63% of the selected studies. This was also found in a 
recent study on cytokine signatures in CFS [15]. Other 
cytokines were only elevated in a minority of studies, 
for example interleukin-1α (IL-1α) in 27% of the studies, 
interleukin 12 (IL-12) in 18%, interleukin 23 (IL-23) 25%, 
and interleukin 8 (IL-8) in 29% of studies. Some stud-
ies only found differences when differentiating between 
patients with long and short illness duration [9, 16].
In order to make progress on the role of the immune 
system in CFS/ME, we have to critically review the stud-
ies that have been performed, and try to clarify the rea-
sons for these discrepancies. When measuring circulating 
cytokines, several issues have to be taken into account. 
First, patient selection is important. Studies often com-
bine different cohorts of patients, recruit employees as 
controls, or controls who participated in previous studies 
[9, 17], and this may lead to different pre-analytical pro-
cedures. The latter is especially an important issue in this 
context. Cytokines may be released ex  vivo by different 
circulating cells, and collection tubes, storage time, num-
ber of freeze–thaw cycles, and processing protocols have 
been found to be of major influence [18, 19]. To make 
a reliable comparison between patients and controls, 
especially in CFS/ME where circulating cytokines are 
expected to be low, it is essential that the pre-analytical 
process in these groups is identical.
Another important issue is the type of analysis used 
to determine cytokine concentrations. Most studies 
measuring cytokines use antibody based enzyme-linked 
immuno sorbent assays (ELISA) [14]. However, limita-
tions of this technique are that multiplex forms of the 
assays often use only one antigen-binding antibody to 
detect the protein, which limits detection specificity as 
well as sensitivity [20]. Sandwich ELISA achieves better 
performance by using pairs of antibodies for each tar-
geted protein, but the assays typically need relatively large 
sample volumes for analyses of single protein species, 
limiting throughput and spending precious samples. By 
contrast, the proximity extension assay (PEA) uses dual 
antibody recognition with oligonucleotide-conjugated 
antibodies in multiplex assays with modest requirements 
for sample volumes [20, 21]. Upon simultaneous binding 
of the correct pair of antibodies, their attached oligonu-
cleotides anneal to each other and can be enzymatically 
extended, forming specific DNA sequences that can be 
quantified using quantitative real-time polymerase chain 
reactions (qPCR).
In this study, cytokine profiles of female CFS/ME 
patients participating in a randomized controlled trial 
on the effect of IL-1 inhibition on fatigue severity [22] 
were compared with age- and gender-matched healthy 
neighborhood controls. The rationale of this RCT was 
that IL-1—despite the fact that it is notoriously difficult 
to measure in the circulation—may play a pathophysi-
ological role in CFS, and its activity may be confined to 
the brain compartment [23]. In addition to the cytokines 
included in the PEA platform, TGF-β and the IL-1 recep-
tor antagonist (IL1-Ra), were measured separately using 
an ELISA. Pre-analytical procedures were identical for 
patients and controls. Furthermore, the effect of IL-1 
inhibition using the IL-1-receptor antagonist anakinra 
for 1 month on circulating cytokine concentrations was 
assessed. As reported in detail elsewhere, the study did 
not demonstrate a beneficial therapeutic effect in these 
patients [24].
Methods
Patients and design
All patients participated in a double-blind randomized 
controlled trial (RCT) on the effect of IL-1 inhibition on 
CFS/ME-related symptoms, of which the results were 
reported elsewhere [24]. The study was conducted at the 
Department of Internal Medicine and Expert Center for 
Chronic Fatigue (ECCF) of the RadboudUMC, Nijmegen, 
the Netherlands. Details of the study were described pre-
viously [22]. In short, fifty female patients between 18 
and 59 years old were included when they fulfilled the 
CDC criteria for CFS/ME [1, 2]. As recommended by 
the CDC criteria, patients can only be included when 
the body mass index (BMI) is ≤  40  kg/m2. Main exclu-
sion criteria were the presence of a somatic disease that 
could explain severe fatigue (sleep apnea, anemia, etc.), 
psychiatric comorbidity (e.g. depression, anxiety disor-
ders) or the use of medication (with the exception of oral 
contraceptives and paracetamol). Patients were asked 
to bring a healthy, female, neighborhood control, with-
out complaints of fatigue and within the same age range 
(± 5 years), to their first study visit.
After inclusion, patients were randomized 1:1 to 
either daily subcutaneous (s.c.) injections with anak-
inra (100 mg/day) or placebo (mixture of sodium citrate, 
sodium chloride, and polysorbate) for a duration of four 
weeks. Controls did not receive an intervention. Anak-
inra and placebo were provided by the Swedish Orphan 
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Biovitrum (Sobi, Stockholm, Sweden). The randomiza-
tion list was computer-generated by the Department of 
Pharmacy [25]. Patients administered the study medi-
cation at home on a daily basis. Both the placebo and 
anakinra syringes had an identical appearance, and drug 
adherence was evaluated as described previously [22, 24].
All participants provided written and oral informed 
consent before inclusion. The hospitals’ ethics commit-
tee approved the study protocol (2014/025). The study 
was performed in accordance with the declaration of 
Helsinki.
Questionnaires
Fatigue was measured in both patients and controls 
using the fatigue severity subscale of the checklist indi-
vidual strength (CIS), which has been used frequently in 
CFS/ME patients [26, 27]. Scores on the CIS-f can vary 
between 8 and 56, and a score ≥ 35 reflects severe fatigue 
[28]. Psychological distress was measured with the total 
score on the Symptom Checklist-90 (SCL-90) [29].
Peripheral blood collection
Morning blood samples were collected from all patients 
prior to the first s.c. injection, and after 4 weeks of treat-
ment. Samples of controls were collected and processed 
simultaneously with those of patients before treatment. 
There were no specific instructions with respect to food 
intake prior to blood sampling. Venous blood was col-
lected in EDTA tubes, and kept on ice until centrifuga-
tion, which was performed within 2–3 h. Next, samples 
were centrifuged at 2960×g for 10  min at 4  °C. Plasma 
aliquots were then frozen at − 80 °C for a maximal dura-
tion of 2 years. Analyses for all patients and controls were 
run at the same time.
PEA assay
Inflammation biomarker profiles were analyzed by 
the analysis service of Olink Proteomics AB (Uppsala, 
Sweden), using their PEA based Proseek© Multiplex 
Inflammation  panel96*96 [21, 29, 30]. This analysis simul-
taneously measures 92 selected inflammatory proteins, 
listed in Additional file 1, using only 1 μL of plasma. For 
each protein, there are two separate antibodies connected 
to one oligonucleotide each. After binding by the anti-
body pair to its target, the 3′ ends of the oligonucleotides 
hybridize, priming a DNA polymerization reaction that 
forms a protein-specific reporter DNA-sequence for each 
detected protein molecule. The reporter DNA strands are 
then quantified using qPCR. Four internal controls and 
two external controls were included in each assay. The 
raw Cq values were normalized for variation between 
and within runs and converted into Normalized Protein 
Expression Units (NPX). The NPX values are expressed 
on a Log2 scale where one unit higher NPX values repre-
sent a doubling of the measured protein concentrations. 
This arbitrary unit can be used for relative quantifica-
tion of proteins and comparing the fold changes between 
groups.
Based on the CFS/ME literature, 20 cytokines were 
selected to be of special interest; CD40L (CD40 ligand), 
CXCL-9 (chemokine ligand 9), CXCL-10 (chemokine 
ligand 10), CCL-2 (MCP-1), CCL-11 (eotaxin), IFN-γ 
(interferon gamma), IL-1α (interleukin-1 alpha), IL-2 
(interleukin-2), IL-4 (interleukin-4), IL-6 (interleukin-6), 
IL-7 (interleukin-7), IL-8 (interleukin-8), IL-10 (interleu-
kin-10), IL-12p40 (interleukin-12 subunit p40), IL-17A 
(interleukin-17A), CSF-1 (macrophage colony-stimulat-
ing factor 1), TNF-β (tumor necrosis factor-beta), TRAIL 
(TNF-related apoptosis-inducing ligand), TGF-α (trans-
forming growth factor alpha), and TNF (tumor necrosis 
factor) [9, 14, 31].
Elisa
Total TGF-β1 levels were measured by sandwich ELISA 
as described in detail previously (R&D systems) [32]. All 
samples were acid activated to activate latent TGF-β (1 M 
hydrochloric acid, 30  min, room temperature). Analysis 
was performed at the Leiden University Medical Center. 
IL-1Ra ELISA (R&D systems) was performed at the Rad-
boud University Medical Center.
Statistical analysis
Study data were analyzed using IBM SPSS statistic 
package version 22 and R [33]. All continuous variables 
are presented as means and standard deviations (SD) 
or medians and ranges, and categorical variables as 
percentages.
Inflammatory markers were excluded if  >  25% of the 
measurements were below the detection limit. Remain-
ing missing values were imputed with a random value 
between 0 and the LOD for the protein at hand, a method 
that avoids the artificial reduction of the standard devia-
tion that is a consequence of imputing the values LOD/2 
or LOD/√2. For the baseline comparison of twenty pre-
selected cytokines, analysis of covariance (ANCOVA) 
was performed with age and BMI added as covariates. 
Based on the result of a previous study, the same analy-
sis was repeated dividing the patient group into patients 
with a long illness duration (> 3 years) and patients with a 
short illness duration [9].
In order to establish a predictive model, a logistic 
regression model was selected using the LASSO regres-
sion strategy that aims at eliminating predictors with 
only marginal predictive performance [34]. As potential 
predictors for CFS/ME, the cytokine concentrations sup-
plemented with age and BMI were used. To determine 
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the performance of this model, the area under the ROC-
curve (AUC) was calculated [35]. As the model is evalu-
ated in the same population that is used for construction, 
the predictive performance will be overestimated. To cor-
rect for this optimism, new populations were generated 
using bootstrap sampling. In each population the same 
modeling strategy was used. Each prediction model was 
then evaluated in both the bootstrap population and the 
original population. After 500 repetitions of this process, 
the differences between performance in bootstrapped 
samples and the original population were used to esti-
mate the optimism due to internal validation [36].
To determine the influence of IL-1Ra on cytokine 
concentrations, analysis ANCOVA was used with the 
cytokine concentration after 4 weeks as dependent vari-
able, treatment as fixed factor, and concentration at base-
line, age, and BMI as covariates.
Results
Patient characteristics
A total of 50 CFS/ME patients and 48 age-matched, 
neighborhood controls were included in the study. Two 
patients were not able to bring a healthy control at base-
line. Table  1 displays demographic and fatigue-related 
characteristics. Within the CFS/ME group, there were 
21 patients with a short illness duration (≤ 3 years, 58%) 
and 29 patients with a long illness duration (>  3  years, 
42%). As expected, CFS/ME patients had a higher 
CIS-fatigue score than controls (52  ±  4 vs. 20  ±  11, 
p < 0.001). Total score on psychological distress was also 
significantly higher in patients (150 ±  30 vs 119 ±  32, 
p  <  0.001). BMI, ethnicity, and percentage of patients 
using oral contraceptives did not significantly differ 
between groups.
CFS/ME patients versus controls
Twenty pre-selected cytokines were compared between 
patients and controls, based on the recent CFS/ME liter-
ature [9, 14, 31]. For IFN-γ, IL-1α, IL-2, IL-4, IL17A, and 
TNF, more than 25% of samples was under the LOD in 
both patients and controls. Results for the remaining 14 
cytokines are displayed in Fig. 1. In this exploratory anal-
ysis, both IL-12b and CSF-1 appeared to be elevated in 
CFS/ME patients (p value 0.004 and 0.049 respectively). 
Other cytokines did not differ between patients and con-
trols. Dividing the patient group into those with short ill-
ness duration, and those with longer illness duration did 
not change these results (data not shown).
There were no differences in TGF-β1 concentrations 
between patients and controls, as determined by ELISA 
(4520 ± 499 pg/mL versus 5972 ± 1279 pg/mL). IL-1Ra 
concentrations did not differ between patients and con-
trols before anakinra treatment (Fig. 2).
Prediction model
Of the 92 proteins measured, 22 appeared to be below 
the detection limit for > 25% of samples for both patients 
and controls (IFN-γ, IL-1α, IL-2, IL-4, IL17A, TNF, MCP-
3, IL-17c, IL-20Ra, IL-2Rb, TSLP, IL-10Ra, IL-22Ra1, 
PD-L1, IL-24, IL-13, ARTN, IL-20, IL-33, LIF, NRTN, 
and IL-5). Although theoretically there is still informa-
tion in the recorded concentrations for these cytokines, 
these proteins were excluded from the analysis as they 
were considered not to be candidates with a substantial 
predictive potential. The remaining 70 proteins were 
entered into the LASSO regression analysis in addition to 
age and BMI. Out of this total of 72 variables entered, 47 
appeared in the final regression model (Table 2). 22 vari-
ables had a positive association with the risk of being a 
CFS/ME patient, and a negative association was present 
for 23 variables. To determine the performance of this 
model, an AUC was calculated with correction for opti-
mism. Optimism in the current model was 0.265, which 
resulted in a corrected AUC value of 0.734.
Influence of IL‑1Ra on circulating cytokines
In accordance with the analysis of patients versus con-
trols, in 22 cytokines the NPX value was below the detec-
tion limit in more than 25% of cases. These cytokines 
were excluded from the analysis. One patient in the anak-
inra group discontinued treatment after 2  weeks as a 
consequence of an adverse event and was excluded from 
the analysis. IL-1α, a cytokine of special interest, was 
not detectable in more than 75% of samples both before 
and after treatment. In Fig.  3 the influence of anakinra 
vs placebo is displayed for all detectable cytokines with 
corresponding 95% confidence intervals (95% CI). In the 
Table 1 Baseline characteristics of chronic fatigue syn-
drome patients (CFS/ME) and healthy controls (HC)
Data are number (%), mean (SD), or median [range]
CIS checklist individual strength, SCL-90 symptom checklist 90, N/A not 
applicable
CFS/ME (n = 50) HC (n = 48) P value
Age, years 31 (10) 31 (10) 0.98
Ethnicity
Caucasian (%)
Other (%)
49 (98)
1 (2)
47 (98)
1 (2)
0.37
Body mass index, kg/m2 25.1 (4.5) 24.9 (4.4) 0.88
Oral contraceptives (%)
Paracetamol (%)
22 (44)
22 (44)
16 (33)
8 (16)
0.28
0.002
Illness duration, months
≤ 3 years (%)
> 3 years (%)
43 [7–109]
29 (58)
21 (42)
N/A
Fatigue severity (CIS-fatigue) 52 (4) 20 (11) < 0.001
Psychological distress (SCL-
90)
150 (30) 119 (32) < 0.001
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IL-8, p=0.62
CF
S HC
0
50
100
150
200
400
420
440
460
480
500
N
PX
IL-7, p=0.97
CF
S HC
0
10
20
30
40
50
N
PX
IL-6, p=0.30
CF
S HC
0
20
40
60
N
PX
MCP-1, p=0.92
CF
S HC
0
500
1000
1500
2000
N
PX
TRAIL, p=0.21
CF
S HC
0
200
400
600
800
1000
N
PX
CXCL-9, p=0.99
CF
S HC
0
200
400
600
800
1000
3000
3200
3400
3600
3800
4000
N
PX
TGFα, p=0.16
CF
S HC
0
1
2
3
4
5
10
11
12
13
14
15
N
PX
CCL11, p=0.99
CS
F HC
0
100
200
300
400
N
PX
IL-12b, p=0.0042
CF
S HC
0
10
20
30
40
50
N
PX
IL-10, p=0.30
CF
S HC
0
10
20
30
40
50
N
PX
CXCL10, p=0.16
CF
S HC
0
1000
2000
3000
N
PX
CD40L, p=0.88
CF
S HC
0
1000
2000
3000
N
PX
TNFβ , p=0.43
CF
S HC
0
20
40
60
N
PX
CSF1, p=0.049
CF
S HC
0
100
200
300
400
500
N
PX
Fig. 1 Normalized Protein Expression Units (NPX) values for patients with chronic fatigue syndrome (CFS/ME, n = 50) compared to healthy controls 
(HC, n = 48). Displays linear NPX values for patients and controls. P values were derived by analysis of covariance
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anakinra group there appeared to be an inhibiting effect 
of anakinra on CSF-1, IL-18R1, and ENRAGE. In addi-
tion there was a stimulating effect on CXCL-9; for the 
remaining variables there was no influence of anakinra. 
As expected, IL-1Ra was significantly higher in those 
patients treated with anakinra (p < 0.001, Fig. 2). Of the 
25 patients treated with anakinra, 23 patients had a con-
centration above the detection limit of 2000 pg/mL.
Discussion
In this study differences in plasma cytokine profiles of 50 
CFS/ME patients compared to 48 healthy age-matched 
neighborhood controls were evaluated using a PEA pro-
tein assay. The concentration of IL-12p40 and CSF-1 were 
significantly higher in CFS/ME patients. For the remain-
ing cytokines of interest based on the current CFS/ME 
literature, no differences could be found comparing them 
individually. However, using the complete inflamma-
tory profile, patients and controls could be discriminated 
using 22 variables with a positive association and 24 vari-
ables with a negative association.
IL-12b, also known as IL-12p40, was significantly 
higher in CFS/ME patients compared to healthy controls 
(p =  0.005). The IL-12p40 subunit is expressed by acti-
vated dendritic cells (DC) and combines with either sub-
unit p35 or p19, to form IL-12 or IL-23 [37]. IL-12 targets 
T-cells and NK-cells, in which it induces IFN-γ produc-
tion [38]. IL-23 has an important role in Th17 produc-
tion, has an effect on memory T-cells, and appears to be 
critical in cerebral autoimmune inflammation [39]. Previ-
ous studies in CFS/ME patient also found increased con-
centration of both IL-12 [17, 40, 41], IL-12b [9] and IL23 
[42]. A relationship between IL-12 and fatigue has been 
established in studies investigating the effect of admin-
istration of human recombinant IL-12 to treat ovarian 
cancer, and head and neck cancer [43, 44]. A proportion 
of treated patients developed fatigue, and combined with 
other side effects such as fever and chills, this toxicity 
had dose-limiting consequences. Furthermore, increased 
concentrations of IL-12 and IL-23 have especially been 
associated with multiple sclerosis, in addition to psoria-
sis, inflammatory bowel disease, cancer and rheumatoid 
arthritis [37]. However, in the light of the explorative 
nature of the current analysis, replication of this finding 
is important.
Increased concentrations of CSF-1 have not been previ-
ously been reported in CFS. CSF-1 or macrophage colony-
stimulating factor (M-CSF) is a hematopoietic growth 
factor involved in proliferation and differentiation of mono-
cytes and macrophages. Targeting CSF-1 has predomi-
nantly been described in cancer, where there appears to 
be an advantage when it is used in combination with other 
immune therapies [45]. Interestingly, the role of CSF-1 in 
the development of sickness behavior has recently been 
assessed by Müller et al. [46]. In this study, neutralization of 
the CSF-1 receptor prevented the development of sickness 
behavior in mice treated with an inflammatory stimulus. 
This behavioral response was mediated through increased 
IL-10 production. Increased IL-10 concentrations were also 
demonstrated in the hypothalamus, where the behavioral 
effect is most likely to be effected.
In contrast to the majority of previous studies measur-
ing circulating cytokines, in this study there were no dif-
ferences in TGF-β concentrations [14]. TGF-β influences 
cell proliferation, migration, and differentiation, and is 
known for its dual role in cancer [47]. TGF-β is released 
in large quantities by activated platelets [48]. Several fac-
tors, such as blood sampling procedures [49] and use of 
medication, influence the extent of platelet activation. A 
possible explanation for the increased TGF-β levels pre-
viously reported might be caused by differences in sample 
handling and drug use, which has recently been demon-
strated [50]. In a recent CFS study, elevated TGF-β were 
also reported [15]. The method used by these investiga-
tors does not allow to assess the magnitude of the TGF-β 
concentrations, and there is little mention of potential 
confounder. For example, oral contraceptives induce 
platelet activation in humans [51], and directly cause 
increased TGF-β concentrations in rats [52].
These differences regarding sample handling might also 
be the explanation for the fact that previous studies found 
more cytokines to be differentially expressed in CFS/ME 
patients. A substantial proportion of studies included 
multiple cohorts in their analyses [9, 31], and although 
this gives the opportunity to investigate a larger number 
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Fig. 2 Concentration of IL-1Ra for patients treated with either 
anakinra or placebo. Displays IL-1Ra concentrations ± SEM in patients 
treated with either anakinra or placebo before and after treatment
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of patients, including patients coming from geographi-
cally different regions results in an inherent danger of 
inaccurate conclusions. This is because sample handling 
may have been different, for example use of different 
centrifuges, differences in ambient temperature, varia-
tions in collection time, and storage. Such differences in 
pre-analytic sample handling and storage, were part of the 
explanation for the spurious reports on the role of murine 
retroviruses in CFS/ME [53]. In addition, cytokine con-
centrations are known to be influenced by drug use. The 
use of non-steroidal anti-inflammatory drugs (NSAIDS), 
which are frequently used by CFS/ME patients, increase 
the production of various cytokines [54, 55]. Differences 
in use of NSAIDS and other medication between patients 
Table 2 LASSO regression analysis: factors associated 
with the risk of being a CFS/ME patient versus healthy con-
trols
Given associations are all conditional on the other predictors
Protiens that are positively associated 
with the risk of being a CFS/ME patient:
Proteins that are nega‑
tively associated with the 
risk of being a CFS/ME 
patient:
Protein Weight Protein Weight
TWEAK 5077 BetaNGF − 6683
CCL4 4182 LIFR − 4053
IL12B 3898 HGF − 2153
CDCP1 3611 CXCL6 − 1849
VEGFA 3138 4EBP1 − 1317
CSF1 2810 SCF − 1307
IL10RB 1737 MMP1 − 1256
CCL11 1354 ADA − 1237
CD5 1087 CXCL10 − 1223
MCP1 1047 IL18R1 − 1076
CASP8 0865 CXCL9 − 0697
FGF5 0758 CCL28 − 0611
IL6 0737 CCL25 − 0557
CCL23 0591 OSM − 0544
CX3CL1 0568 CCL20 − 0514
ST1A1 0307 CCL19 − 0507
TNFSF14 0303 TRANCE − 0498
CD244 0302 NT3 − 0489
IL10 0287 MCP4 − 0458
CXCL5 0245 TRAIL − 0406
LAPTGFbeta1 0166 ENRAGE − 0356
OPG 0107 CD6 − 0109
TNFB − 0062
MMP10 − 0033
FGF23 − 0017
Optimism: 0.2652
AUC: 0.9996
Corrected AUC: 0.7344
Fig. 3 Treatment effect of the 4 week intervention period on 
circulating cytokines. Displays the difference and 95% confidence 
intervals between study arms for protein values after treatment 
(anakinra:controls)
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and controls, might have explained the reported increased 
levels of pro-inflammatory cytokines in previous studies.
Interestingly, combining all inflammatory markers 
yields a prediction model containing 47 markers with a 
corrected AUC of 0.73. To control for optimism, a boot-
strapping method was used, which yielded a high cor-
rection factor of 0.265. Some of the measured proteins 
have a positive association with CFS/ME (IL-6, CSF-
1), whereas for others there was a negative association 
(BetaNGF, CXCL-6). This selection of inflammatory 
markers could be a starting point for further studies 
investigating potential diagnostic markers in CFS/ME.
According to the 95% confidence intervals, there was 
an inhibiting effect of anakinra on circulating CSF-1, IL-
18R1 and ENRAGE and a stimulating effect on CXCL-9. 
Given the large numbers of cytokines tested, these find-
ings have to be interpreted with caution. It is important 
to mention that IL-1β was not included in the analysis, 
and IL-α was already below the detection limit before 
treatment in 82% of samples. It was expected that there 
would be a significant decrease of IL-6 in the anakinra 
group, as IL-1 induces IL-6 production, and is frequently 
used as a readout for IL-1 activity [56]. In previous stud-
ies, there was also a significant reduction of IL-6 concen-
trations after anakinra treatment. This was investigated 
in patients intravenously treated after stroke [57] and 
patients treated with subcutaneous injections for heart 
failure [58]. A possible explanation for the lack of a 
decrease in IL-6 concentrations is that in comparison to 
the situation in stroke patients where it has an important 
prognostic role [59], CFS/ME patients exhibit no increase 
of this cytokine at baseline. In stroke and heart failure an 
inflammatory response in which IL-1 plays a key role is 
now well established, but it is possible that IL-1 does not 
play a role in CFS. Since drug adherence was excellent, 
which is also reflected by the significant increase of IL-
1Ra in the anakinra treated group, it is unlikely that lack 
of compliance is an explanation for this result.
This study has several strengths. To our knowledge, 
PEA-based assays have not previously been performed in 
CFS/ME patients. Over the past few years, there has been 
a search for sensitive methods to measure multiple inflam-
matory markers simultaneously in order to find potential 
biomarkers for CFS/ME. However, this is most commonly 
performed using multiplex bead-based immunoassays, 
that have limited sensitivity and specificity [20]. This is not 
the case for the PEA method, which has a much higher 
specificity as the signals can only be elicited by the cog-
nate antibody pairs, while cross reactions between irrel-
evant antibody pairs are ignored [21]. Another asset of 
this study is the inclusion of neighborhood controls. Each 
patient was asked to bring a healthy, sex- and age-matched 
control, and blood withdrawal of both patient and control 
took place at the same time. Pre-analytic processes were 
identical, which was not the case in most of the previously 
published biomarker studies in CFS/ME [31, 41]. The third 
advantage of the current study is exclusion of patients who 
use medication, with the exception of oral contraceptives 
and paracetamol. CFS/ME patients frequently use a sig-
nificant amount of medication, in a recent study 64% of 
patients used complementary and alternative medicine 
[60]. Another study found that > 90% of CFS/ME patients 
use at least one drug or supplement, especially antidepres-
sants, sedatives and muscle relaxants [61].
A limitation of this study is the relatively small num-
ber of patients included measuring a large number of 
variables. However, this has been accounted for using 
the LASSO method for logistic regression, which is an 
elegant variable reduction method [62]. However, con-
sidering the large factor for optimism, the prediction 
model has to be interpreted with caution. Another limi-
tation of the current study is the fact that IL-1β was not 
measured in plasma samples, although the value of this 
measurement is limited as IL-1β is usually undetectable 
in peripheral blood, even with the PEA method.
Conclusion
In conclusion, this study demonstrated increased IL-
12p40 and CSF-1 concentrations in CFS/ME patients 
in addition to a set of predictive biomarkers. There was 
no effect of anakinra on circulating cytokines other than 
IL-1Ra. As emphasized in this study, sample handling 
and diagnostic procedures are very important when 
measuring cytokines. Future studies should take this 
into account and in order to replicate findings, methods 
should be extensively reported.
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